NCT00936546已完成2 期
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Testing the safety of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.
研究概览
简要总结
This study will evaluate the safety and efficacy of the combination of rituximab and methotrexate to treat disabling fibrosing skin disorders.Rituximab will be administered at baseline and month 6. The drug will be considered efficacious if the skin thickness diminishes substantially.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(Fe) male >, = 18 years
- •Fibrosing skin disorder, not fulfilling the ACR criteria for diffuse SSc
- •Inadequate response to methotrexate (at least 12 weeks 10 mg/w, except if not tolerated or contra-indicated
- •Debilitating disease defined by either one of the following:
- •Restriction of mobility
- •Disfiguration: eg: facial involvement
- •Severe Internal Organ involvement
- •Contraception for women with childbearing potential. Sexual abstinence is an alternative to contraception.
排除标准
- •FVC<, = 50%
- •LVEF<, = 40% of predicted value,
- •DLCO<, = 40% of predicted value
- •Exclusion criteria as specifically described in the protocol for anti-CD-20:
- •Lack of peripheral venous access.
- •Pregnancy or breast feeding.
- •Significant cardiac or pulmonary disease (including obstructive pulmonary disease).
- •Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the investigator's opinion, would preclude patient participation.
- •Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.
- •Known active infection of any kind (excluding fungal infections of mail beds), or any major episode of infection requiring hospitalization or treatment with i.v. anti-infectives within 4 weeks of baseline or completion of oral anti-infectives within 2 weeks prior to baseline.
- •History of deep space/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within 52 weeks prior to baseline.
- •History of serious recurrent or chronic infection (for screening for a chest infection a chest radiograph will be performed at screening if not performed within 12 weeks prior to screening).
- •History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured).
- •History of a severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of rituximab or to murine proteins.
- •Concurrent treatment with any biologic agent or DMARD other than MTX. Treatment must be discontinued 14 days prior to baseline , except for the following: azathioprine for ≥ 28 days; leflunomide for ≥ 8 weeks (or ≥ 14 days after 11 days of standard cholestyramine or activated charcoal washout); infliximab ≥ 8 weeks; adalimumab ≥ weeks.
- •Previous treatment with > 1 biological agent.
- •Treatment with any investigational agent within 28 days of baseline or 5 half-lives of the investigational drug (which ever is the longer).
- •Receipt of any vaccine within 28 days prior to baseline
- •Intolerance or contraindications to i.v. glucocorticoids.
- •Positive serum human chorionic gonadotropin (hCG) measured at screening or a positive pregnancy test prior to the first rituximab infusion.
- •Positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C serology.
- •Hemoglobin < 8.0 g/dL.
- •Concentrations of serum IgG and/or IgM below 5.0 and 0.40 mg/mL, respectively.
- •Absolute neutrophil count (ANC) < 1.5 X 10³/µL.
研究组 & 干预措施
Rituximab
Experimental
干预措施: Rituximab (Drug)
结局指标
主要结局
Testing the safety of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.
时间窗: Safety will be evaluated at baseline, month 3, 6, 12, 15, 18, 24, 36, 48 and 60.
次要结局
- Testing the efficacy of anti-CD-20 in a small cohort of patients with debilitating fibrosing skin disorders.(Efficacy will be evaluated at baseline, month 3, 6, 12, 15, 18, 24, 36, 48 and 60.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha TherapyRheumatoid ArthritisNCT00468546Hoffmann-La Roche520
进行中（未招募）
不适用
A protocol based treatment for debilitating fibrosing skin disorders with (anti-CD-20), rituximabFibrosing skin disordersEUCTR2009-012034-70-BEniversity Hospital Ghent
招募中
2 期
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLPrimary CNS LymphomaNCT05425654National Research Center for Hematology, Russia30
Unknown
4 期
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT04083066Mingzhi Zhang20
尚未招募
不适用
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary CNS lymphomaKCT0003146Samsung Medical Center35